Organon Teknika gives up on hepatitis C
This article was originally published in Clinica
Organon Teknika, the diagnostics subsidiary of Akzo Nobel, has given up its fight for a share in the hepatitis C testing market. This leaves only Murex squaring up to UK and European HCV patent holder Chiron. Murex is appealing against unfavourable court decisions in the UK and the Netherlands.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.